Biomerica adds Harry Leider, MD, MBA to Strategic Advisory Board
April 19 2018 - 8:19AM
Biomerica, Inc. (Nasdaq:BMRA) today announced that it has added
Harry L. Leider, MD, MBA to its Strategic Advisor Board, which is
chaired by Edward W. (Ned) Barnholt.
Until recently, Dr. Leider served as Chief Medical Officer (CMO)
and Group Vice President of Walgreens. As the CMO at
Walgreens, he provided executive leadership for health analytics,
clinical program development, and clinical sales solutions.
Dr. Leider also served as the senior clinical spokesperson
for the company and routinely represented Walgreens with leaders in
government, managed care, health systems, and other healthcare
organizations. As Chief Medical Officer, he led a
cross-functional department of over 40 professionals that conducted
over 60 health outcomes studies that demonstrated the value of
Walgreens programs and services. He also had leadership
responsibility for a team that evaluated over 200 emerging
healthcare technologies to provide information about potential M
& A and partnership opportunities. Notably, Dr. Leider also
directed the clinical design for a digital health programs that
rewards 3 million Walgreens customers for taking steps to improve
their health.
Prior to Walgreens, Dr. Leider was the Chief Medical Officer of
Ameritox which was the nation’s largest specialty lab serving
clinicians who treat chronic pain and behavioral health conditions.
He was responsible for the development of all provider support and
research programs, and played a key role supporting sales efforts
directed at providers and payors. Prior to his role at
Ameritox, Dr. Leider held C-suite positions in several population
health and payor companies.
"Biomerica’s unique InFoods®IBS diagnostic guided therapy now in
trials in the United States, could help alleviate suffering in many
of the 45 Million Americans that suffer from Irritable Bowel
Syndrome (IBS)," stated Dr. Leider.
Zackary Irani, Chairman and Chief Executive Officer, stated, “We
are excited to have Harry join our Strategic Advisory Board.
His expertise and recognized leadership in cutting edge healthcare
will be invaluable in helping us launch the InFoods® IBS product
worldwide once approved.”
About Biomerica (NASDAQ:BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical
company that develops, manufactures and markets advanced diagnostic
products used at the point-of-care (in home and in physicians'
offices) and in hospital/clinical laboratories for the early
detection of medical conditions and diseases. The Company's
products are designed to enhance the health and well-being of
people, while reducing total healthcare costs. Biomerica primarily
focuses on products for Gastrointestinal Disease, Diabetes and
esoteric testing.
The Biomerica InFoods® IBS product identifies patient specific
foods that when removed may alleviate an individual's IBS symptoms.
This patent-pending, diagnostic-guided therapy is designed to allow
for a patient specific, guided dietary regimen to improve Irritable
Bowel Syndrome (IBS) outcomes. The point-of-care product is being
developed to allow physicians to perform the test in-office using a
finger stick blood sample while a clinical lab version of the
product will be the first for which the company will seek
regulatory approval. A billable CPT code that can be used by both
clinical labs and physicians' offices is available for InFoods®
diagnostic products. Since the InFoods® product is a
diagnostic-guided therapy, and not a drug, it has no drug type side
effects.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking; such as
statements relating to intended launch dates, sales potential,
significant benefits, market size, prospects, new products,
favorable outlook, new distributors, expansion, increases in
productivity and margins, expected orders, leading market
positions, anticipated future sales or production volume of the
Company, the launch or success of product and new product
offerings. Such forward-looking information involves important
risks and uncertainties that could significantly affect anticipated
results in the future, and accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. The potential risks and
uncertainties include, among others, fluctuations in the Company's
operating results due to its business model and expansion plans,
downturns in international and or national economies, the Company's
ability to raise additional capital, the competitive environment in
which the Company will be competing, and the Company's dependence
on strategic relationships. The Company is under no obligation to
update any forward-looking statements after the date of this
release.
Contact(s):
Zack Irani | CEOp. 949.645.2111www.biomerica.com
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Biomerica (NASDAQ:BMRA)
Historical Stock Chart
From Apr 2023 to Apr 2024